chevron_leftBack
As of 14 June 2026, CNS Pharmaceuticals, Inc. has a market cap of $1.83M USD, ranking #47390 globally and #6022 in the United States.
It ranks #4200 in the Healthcare sector, and #1328 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.83MUSD
Enterprise Value
-$5.08MUSD
EBITDA (TTM)
-$15.98MUSD
Net Income (TTM)
-$15.85MUSD
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Rami Levin
open_in_new
Employees
5
Founded
2017
IPO
08 Nov 2019
Website
cnspharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.2% | -9.3% | -8.6% | -62% | -72% | -82% |
News
Loading...
CNSP Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CNSP
CNS Pharmaceuticals Inc Ordinary Shares
ISIN: US18978H5081
Shares Out.:
Shares Outstanding:
1.461M1
Shares Float:
1.454M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.26 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
42M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
30M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
20M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
15M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
8M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
6M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
18M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
16M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
15M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
10M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
6M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
6M%
80.96B GBP
|
14.6
|
chevron_leftBack